• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

美登素（NSC 153858）在晚期癌症中的II期评估。一项东南癌症研究组的试验。

Phase II evaluation of maytansine (NSC 153858) in advanced cancer. A Southeastern Cancer Study Group trial.

作者信息

Ravry M J, Omura G A, Birch R

出版信息

Am J Clin Oncol. 1985 Apr;8(2):148-50. doi: 10.1097/00000421-198504000-00007.

DOI:10.1097/00000421-198504000-00007
PMID:3834790
Abstract

Maytansine given in a 3-day course q3 weeks produced only five responses (3%) in 163 evaluable adults with advanced cancer. The dose schedule employed is not recommended for further study.

摘要

每3周一次，连续3天给药的美登素，在163例可评估的晚期癌症成人患者中仅产生了5例有效反应（3%）。所采用的给药方案不建议进一步研究。

相似文献

1
Phase II evaluation of maytansine (NSC 153858) in advanced cancer. A Southeastern Cancer Study Group trial.美登素（NSC 153858）在晚期癌症中的II期评估。一项东南癌症研究组的试验。
Am J Clin Oncol. 1985 Apr;8(2):148-50. doi: 10.1097/00000421-198504000-00007.
2
Maytansine: a phase I study of an ansa macrolide with antitumor activity.
Cancer Treat Rep. 1978 Mar;62(3):435-8.
3
Early clinical study of an intermittent schedule for maytansine (NSC-153858): brief communication.美登素（NSC-153858）间歇性给药方案的早期临床研究：简报
J Natl Cancer Inst. 1978 Jan;60(1):93-6. doi: 10.1093/jnci/60.1.93.
4
Phase II study of maytansine in advanced breast cancer.
Cancer Treat Rep. 1981 May-Jun;65(5-6):536-7.
5
Initial clinical trials of maytansine, an antitumor plant alkaloid.
Cancer Treat Rep. 1978 Mar;62(3):429-33.
6
Phase II trial of maytansine in patients with advanced colorectal carcinoma.美登素用于晚期结直肠癌患者的II期试验。
Cancer Treat Rep. 1978 Aug;62(8):1237-8.
7
Minimal single-agent activity of maytansine in refractory breast cancer: a Southwest Oncology Group study.
Cancer Treat Rep. 1980 Apr-May;64(4-5):675-7.
8
Phase II evaluation of maytansine in patients with advanced head and neck cancer.
Cancer Treat Rep. 1979 Nov-Dec;63(11-12):2061-2.
9
Phase II study of maytansine in advanced sarcomas.
Cancer Treat Rep. 1983 Apr;67(4):401-2.
10
Phase II study of maytansine in patients with advanced lymphomas: an Eastern Cooperative Oncology Group pilot study.
Cancer Treat Rep. 1980 Oct-Nov;64(10-11):1115-7.

引用本文的文献

1
A DM1-doped porous gold nanoshell system for NIR accelerated redox-responsive release and triple modal imaging guided photothermal synergistic chemotherapy.一种掺 DM1 的多孔金纳米壳体系，用于近红外加速的氧化还原响应型释放以及三模态成像引导的光热协同化疗。
J Nanobiotechnology. 2021 Mar 19;19(1):77. doi: 10.1186/s12951-021-00824-5.
2
Targeting and extending the eukaryotic druggable genome with natural products: cytoskeletal targets of natural products.利用天然产物靶向和扩展真核生物可用药基因组：天然产物的细胞骨架靶点。
Nat Prod Rep. 2020 May 1;37(5):634-652. doi: 10.1039/c9np00053d. Epub 2019 Nov 25.
3
Antibody-Drug Conjugates in Breast Cancer: a Comprehensive Review.
抗体偶联药物在乳腺癌中的应用：全面综述。
Curr Treat Options Oncol. 2019 Apr 1;20(5):37. doi: 10.1007/s11864-019-0633-6.
4
Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics.用于靶向癌症治疗的抗体-药物偶联物优化策略与进展
Biomol Ther (Seoul). 2015 Nov;23(6):493-509. doi: 10.4062/biomolther.2015.116. Epub 2015 Nov 1.
5
Recent Advances in the Development of Antineoplastic Agents Derived from Natural Products.天然产物来源抗肿瘤药物研发的最新进展
Drugs. 2015 Nov;75(17):1993-2016. doi: 10.1007/s40265-015-0489-4.
6
Potential of plant-derived natural products in the treatment of leukemia and lymphoma.植物源天然产物在白血病和淋巴瘤治疗中的潜力。
Curr Drug Targets. 2010 Jul;11(7):812-22. doi: 10.2174/138945010791320809.